Imatinib mesylate is an anticancer agent that selectively inhibits protein kinases involved in the pathophysiology of cancer. It is now the first-line therapy for patients with chronic myeloid leukaemia (CML) and is generally well tolerated. Here, we describe a case of a patient receiving imatinib for CML. The patient developed renal failure accompanied by severe hypophosphataemia, hypokalaemia...

In the last decade a tremendous amount has been learned about the biology and treatment of gastrointestinal stromal tumor (GIST). Imatinib mesylate has revolutionized the treatment of metastatic GIST. In addition, the role of imatinib in localized GIST has gained much interest and may improve patient outcomes. Additionally, research efforts aimed at understanding the biology and the molecular h...

background: imatinib mesylate, a small-molecular analog of adenosine triphosphate (atp) that potently inhibits tyrosine kinase activities of bcr–abl, pdgfr-β, pdgfr-α, c-fms, arg and c-kit, is one of the novel molecularly targeted drugs being introduced into cancer therapy. we tested the effect of imatinib on the ovarian histological structure and the concentration of estrogen and progesterone,...

Patients with advanced stages of chronic myeloid leukemia (CML) often manifest imatinib mesylate resistance associated with point mutations in BCR-ABL. AMN107 is a new higher-potency inhibitor of BCR-ABL. To identify mutations in BCR-ABL that could result in resistance to AMN107, a cDNA library of BCR-ABL mutants was introduced into Ba/F3 cells followed by selection in AMN107 (0.125-0.5 microM)...

Imatinib mesylate is effective in the treatment of hematologic malignancies that are characterized by either ablor PDGFR activating mutations. The drug is also active in a subset of patients with eosinophilic disorders and systemic mast cell disease (SMCD). Recently, a novel tyrosine kinase that is generated from fusion of the Fip1-like 1 (FIP1L1) and PDGFR (PDGFRA) genes has been identified as...

Increased angiogenesis in bone marrow (BM) is one of the characteristics of chronic myeloid leukemia (CML), a clonal myeloproliferative disorder that expresses a chimeric Bcr/Abl protein. Recently, the therapeutic strategy in CML has been totally modified with the development of a new drug: imatinib mesylate (STI571), a specific inhibitor of Bcr/Abl tyrosine kinase activity. The aim of our stud...

Imatinib mesylate is a selective Bcr-Abl kinase inhibitor, effective in the treatment of chronic myelogenous leukemia. Most patients in chronic phase maintain durable responses, however, many in blast crisis fail to respond or relapse quickly. Kinase domain mutations are the most commonly identified mechanism associated with relapse. Many of these mutations decrease the sensitivity of the Abl k...

Background About 80% patients with GIST would experience tumor recurrence or metastases after a prior radical resection. The most common metastatic site is liver. Imatinib mesylate was proved to be effective for advanced GIST. Current study was designed to observe the influence of liver metastases to the outcome of imatinib treatment for recurrent GIST from prior surgery. Methods 42 patients ha...